Obesity and Dyslipidemia: How Would You Treat?

Slides:



Advertisements
Similar presentations
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
Advertisements

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
AIM HIGH Niacin plus Statin to prevent vascular events
The Latest Lipid Guidelines:
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
PCSK9 Inhibitors Post-CVOTs
Statin Selection in the Elderly
Optimizing Statin Therapy
An Endocrinology Clinic in Dyslipidemia
Statin Selection Aimed to Reduce New-Onset DM Risk:
Omega-3 Prescriptions vs Supplements in Practice
Back to the Basics of Dyslipidemia
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Advances in Dyslipidemia: What Have We Learned From ACC 2017
Statins and the Elderly Patient
Statin Selection in Special Patient Populations: A Case Challenge
Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Statins and New-Onset Diabetes REAL Updates and Clinical Implications
Statin Class in Session
Diabetes Increases Risk of CVD
Assessing the State of Statin Therapy
An Update on PCSK9 Inhibitors
New Pathways in Lipid Care
What's New in Dyslipidemia?
Statins and Glucose Metabolism: Are All Agents Alike?
Statin Class in Session
PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins
CV Risk Doesn't End in the Cath Lab
Personalizing Statin Therapy in Patients With HIV
A Journal Club on Lipid Management:
PCSK9 Inhibitors and Cardiovascular Outcomes
PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?
Improving Appropriate Access to PCSK9 Inhibitors
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
Statins and HIV:.
Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?
Lipid Clinic Challenge
The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.
CV Risk Doesn't End in the Cath Lab
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.
Statins, Obesity, and Hyperlipidemia
Glucose Management and Statin Therapy
LDL Cholesterol.
How to Optimize Cholesterol Management in High-Risk CV Patients
Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.
Reducing Risk for CV Outcomes
A Family Affair.
New Lipid-Lowering Guidelines
Lipid Updates From Spring 2019
An Update on PCSK9 Inhibitors
Statins and Glucose Metabolism: An Endocrinology Perspective
CHD RISK Glycemia 75g OGTT Time Metabolic Syndrome
Glucose Management and Statin Therapy
Achieving Lipid Targets With PCSK9 Inhibition
Statin Selection in Patients With Pre-Diabetes: Case Considerations
Statin Therapy in Patients With Insulin Resistance
What's New in Oral Combination Therapy for Type 2 Diabetes?
Lipids, the Heart, and the Kidney
ATP III Guidelines Benefit Beyond LDL-Lowering:
Specific Dyslipidemias: Very High LDL Cholesterol (>190 mg/dL)
Presentation transcript:

Obesity and Dyslipidemia: How Would You Treat?

Obesity as a Target Managing Metabolic Syndrome

Case Study: Obesity and Dyslipidemia

ASCVD Risk Calculator Plus Online or in App Form

MESA 10-Year CHD Risk With Coronary Artery Calcification

Who Needs a Statin Risk Calculator?

Statin Metabolism and Race

Back to the Case Labs

Managing This Patient

Patient-Centered Care for the Patient With Obesity

Obesity as an Addiction

Primary Prevention Trials of Lipid-Altering Therapy Including Patients With Diabetes

Secondary Prevention Trials of Lipid-Altering Therapy Including Patients With Diabetes

Certain Statins Increase the Risk of New-Onset T2D

Risk of T2D Lower With Some Statins

Statin Intensity

REAL-CAD

REAL-CAD: Primary Endpoint CV Death/MI/Ischemic Stroke/UA

REAL-CAD Safety Outcomes

DO-IT: Dyslipidemia of Obesity Intervention in Teens Trial

Effects of Pitavastatin on Insulin Sensitivity and Liver Fat Obesity Trial

Achieving Goals With Your Patients

It Takes a Team

Readiness for Change Physical Activity Is a Must -- No Excuses

Key Take-Home Points

Abbreviations

Abbreviations (cont)

Abbreviations (cont)